Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Kwok

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Rheumatology (Oxford, England)|October 15, 2020
Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studiesDésirée van der Heijde, Robert B M Landewé, Jürgen Wollenhaupt, et al.
Annals of the Rheumatic Diseases|August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsChristina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Clinical Rheumatology|January 1, 2022
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)Ruediger B Mueller, Hendrik Schulze-Koops, Daniel E Furst, et al.
Seminars in Arthritis and Rheumatism|July 23, 2016
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitorChristina Charles-Schoeman, Pierre Wicker, Miguel A Gonzalez-Gay, et al.
Annals of the Rheumatic Diseases|April 24, 2015
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeJeffrey R Curtis, Eun Bong Lee, Irina V Kaplan, et al.
Rheumatology and Therapy|December 6, 2021
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib TreatmentKevin L Winthrop, Jeffrey R Curtis, Kunihiro Yamaoka, et al.
Therapeutic Advances in Musculoskeletal Disease|February 13, 2023
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinibLars E Kristensen, Bruce Strober, Denis Poddubnyy, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
RMD Open|May 13, 2020
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisAlexis Ogdie, Kurt de Vlam, Iain B McInnes, et al.
Rheumatology and Therapy|May 16, 2018
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc AnalysesVibeke Strand, Arthur Kavanaugh, Alan J Kivitz, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Rheumatology (Oxford, England)|October 15, 2020
Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studiesDésirée van der Heijde, Robert B M Landewé, Jürgen Wollenhaupt, et al.
Annals of the Rheumatic Diseases|August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsChristina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Clinical Rheumatology|January 1, 2022
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)Ruediger B Mueller, Hendrik Schulze-Koops, Daniel E Furst, et al.
Seminars in Arthritis and Rheumatism|July 23, 2016
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitorChristina Charles-Schoeman, Pierre Wicker, Miguel A Gonzalez-Gay, et al.
Annals of the Rheumatic Diseases|April 24, 2015
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeJeffrey R Curtis, Eun Bong Lee, Irina V Kaplan, et al.
Rheumatology and Therapy|December 6, 2021
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib TreatmentKevin L Winthrop, Jeffrey R Curtis, Kunihiro Yamaoka, et al.
Therapeutic Advances in Musculoskeletal Disease|February 13, 2023
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinibLars E Kristensen, Bruce Strober, Denis Poddubnyy, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
RMD Open|May 13, 2020
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisAlexis Ogdie, Kurt de Vlam, Iain B McInnes, et al.
Rheumatology and Therapy|May 16, 2018
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc AnalysesVibeke Strand, Arthur Kavanaugh, Alan J Kivitz, et al.
Pageof 6